Environmental, Social and Governance Report

Overview

The report covers the Group's 2025 ESG performance across its global pharmaceutical, CDMO and biotech operations. It highlights carbon-reduction targets for 2030, 2035 and 2050 against a 2025 baseline. It reports 50,270.5 tonnes of Scope 1 and 2 emissions and zero work-related fatalities in the past three years, alongside extensive environmental and social programs.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English, Chinese
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services